Select your language/region

Invitation to presentation of Q-linea’s Interim report Q1-2020 on May 7, 2020

Invitation to presentation of Q-linea’s Interim report Q1-2020 on May 7, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – March 2020 on Thursday, May 7, 2020 at 07:30 a.m. CET.
Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on May 7, 2020, at 13:00 – 14:00 p.m CET.

Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Q1 interim report followed by a Q&A-session.

To participate, please call any of the following phone numbers from:

Sweden: + 46 8 505 583 52

UK: + 44 333 300 9261

US: + 1 833 249 8403


For more information, please contact:

Anders Lundin, CFO, Q-linea AB
+46 (0)70-600 15 20

The information was submitted for publication, through the agency of the contact person set out above, at 13:00 CET on April 29, 2020.

About Q-linea

Q-linea is an infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit